Incidence of Legal Blindness From Age-Related Macular Degeneration in Denmark: Year 2000 to 2010

被引:263
作者
Bloch, Sara Brandi [1 ,3 ]
Larsen, Michael [1 ,2 ,3 ]
Munch, Inger Christine [1 ,3 ]
机构
[1] Glostrup Cty Hosp, Dept Ophthalmol, DK-2600 Glostrup, Denmark
[2] Kennedy Ctr, Natl Eye Clin, Glostrup, Denmark
[3] Univ Copenhagen, Fac Hlth Sci, Copenhagen, Denmark
关键词
MACULOPATHY; RANIBIZUMAB; PREVALENCE;
D O I
10.1016/j.ajo.2011.10.016
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
PURPOSE: To report incidence rates of legal blindness from age-related macular degeneration (AMD) and other causes in Denmark from years 2000 to 2010 in the age group at risk of AMD aged 50 years and older. DESIGN: Population-based observational registry study. METHODS: SETTINGS: Membership register of the Danish Association of the Blind, the primary admission criterion of which is best-corrected visual acuity 0.1 (20/200) or lower in a person's better-seeing eye. STUDY POPULATION: A total of 11 848 incident cases of legal blindness from a population of citizens aged >= 50 years numbering 1.71 million in 2000 and 1.87 million in 2010 with free access to a single-payer public health care system. MAIN OUTCOME MEASURES: Incidence rates of legal blindness from AMD from 2000 to 2010. RESULTS: The incidence rate of legal blindness attributable to AMD in citizens aged >= 50 years decreased from 52.2 cases per year per 100 000 in 2000 to 25.7 cases per year per 100 000 in 2010, corresponding to a reduction of 50% (95% confidence interval [CI95]: 45%-56%, P < .0001, adjusted for age), the bulk of the reduction occurring after 2006. The incidence of legal blindness from causes other than AMD decreased by 33% (CI95: 21%-44%, P < .0001), most of the reduction occurring between 2000 and 2006. CONCLUSION: From 2000 to 2010 the incidence of legal blindness from AMD fell to half the baseline incidence. The bulk of the reduction occurred after the introduction of intravitreally injected inhibitors of vascular endothelial growth factor in 2006. (Am J Ophthalmol 2012;153:209-213. (C) 2012 by Elsevier Inc. All rights reserved.)
引用
收藏
页码:209 / 213
页数:5
相关论文
共 18 条
[11]   Age-period-cohort effect on the incidence of age-related macular degeneration - The Beaver Dam Eye Study [J].
Klein, Ronald ;
Knudtson, Michael D. ;
Lee, Kristine E. ;
Gangnon, Ronald E. ;
Klein, Barbara E. K. .
OPHTHALMOLOGY, 2008, 115 (09) :1460-1467
[12]   Prevalence of Age-Related Macular Degeneration in the US Population [J].
Klein, Ronald ;
Chou, Chiu-Fang ;
Klein, Barbara E. K. ;
Zhang, Xinzhi ;
Meuer, Stacy M. ;
Saaddine, Jinan B. .
ARCHIVES OF OPHTHALMOLOGY, 2011, 129 (01) :75-80
[13]   Forecasting Age-Related Macular Degeneration Through the Year 2050 The Potential Impact of New Treatments [J].
Rein, David B. ;
Wittenborn, John S. ;
Zhang, Xinzhi ;
Honeycutt, Amanda A. ;
Lesesne, Sarah B. ;
Saaddine, Jinan .
ARCHIVES OF OPHTHALMOLOGY, 2009, 127 (04) :533-540
[14]  
Rosenberg T, 1996, ACTA OPHTHALMOL SCAN, V74, P399
[15]   Ranibizumab for neovascular age-related macular degeneration [J].
Rosenfeld, Philip J. ;
Brown, David M. ;
Heier, Jeffrey S. ;
Boyer, David S. ;
Kaiser, Peter K. ;
Chung, Carol Y. ;
Kim, Robert Y. .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (14) :1419-1431
[16]   Smoking and age-related maculopathy - The Blue Mountains Eye Study [J].
Smith, W ;
Mitchell, P ;
Leeder, SR .
ARCHIVES OF OPHTHALMOLOGY, 1996, 114 (12) :1518-1523
[17]  
Statistics Denmark, POP EL
[18]  
VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205